GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Selling, General, & Admin. Expense

Xvivo Perfusion AB (Xvivo Perfusion AB) Selling, General, & Admin. Expense : $30.89 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Xvivo Perfusion AB's selling, general, & admin. expense for the three months ended in Mar. 2024 was $8.26 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $30.89 Mil.


Xvivo Perfusion AB Selling, General, & Admin. Expense Historical Data

The historical data trend for Xvivo Perfusion AB's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Selling, General, & Admin. Expense Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.07 12.88 16.87 21.52 30.14

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.43 7.41 7.21 8.01 8.26

Competitive Comparison of Xvivo Perfusion AB's Selling, General, & Admin. Expense

For the Medical Devices subindustry, Xvivo Perfusion AB's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Selling, General, & Admin. Expense Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Selling, General, & Admin. Expense falls into.



Xvivo Perfusion AB Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (OTCPK:XVIPF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Xvivo Perfusion AB Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.